A new wave of biosimilar launches is creating downward pressure on average sales prices (ASPs), disrupting reimbursement to providers, providing opportunities and challenges to payers and GPOs, and upending the gross-to-net math for manufacturers. In this session, we will explore the implications of the ASP death spiral on the drug supply chain and its interplay with price transparency efforts.